Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

HER2/neu testing in primary colorectal carcinoma

(2014) B Ingold Heppner et al.   BRITISH JOURNAL OF CANCER

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

(2014) Maurizio Scaltriti et al.   CLINICAL CANCER RESEARCH

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression

(2014) An Na Seo et al.   PLoS One

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Expression of HER2 in Colorectal Cancer Does Not Correlate with Prognosis

(2013) Wiesław Janusz Kruszewski et al.   DISEASE MARKERS

Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

(2013) Carlos Gomez-Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitation of HER2/neuExpression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis

(2012) Jennifer Jeung et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

(2010) S Guiu et al.   BRITISH JOURNAL OF CANCER

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers

(2010) Andreas H. Marx et al.   HUMAN PATHOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer

(2010) Marta Herreros-Villanueva et al.   MOLECULAR BIOLOGY REPORTS

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

(2009) Dara O Kavanagh et al.   BMC CANCER

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

(2008) Giuseppe Gullo et al.   INVESTIGATIONAL NEW DRUGS

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

(2008) Allen M Gown et al.   MODERN PATHOLOGY

Letter to the Editor

(2008) Wedad M Hanna et al.   MODERN PATHOLOGY